Yifeng Pharmacy
Yifeng Pharmacy Chain Co., Ltd. engages in the retail business of pharmaceutical products in China. The company operates through Retail business and Wholesale business segments. It offers Western and Chinese patent medicine, traditional Chinese medicine herbal pieces, medical devices and equipment, health supplements and products, personal care products, drugs, and convenience products related to… Read more
Yifeng Pharmacy (603939) - Net Assets
Latest net assets as of September 2025: CN¥11.66 Billion CNY
Based on the latest financial reports, Yifeng Pharmacy (603939) has net assets worth CN¥11.66 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥26.07 Billion) and total liabilities (CN¥14.41 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥11.66 Billion |
| % of Total Assets | 44.73% |
| Annual Growth Rate | 30.54% |
| 5-Year Change | 97.05% |
| 10-Year Change | 702.72% |
| Growth Volatility | 39.15 |
Yifeng Pharmacy - Net Assets Trend (2011–2024)
This chart illustrates how Yifeng Pharmacy's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Yifeng Pharmacy (2011–2024)
The table below shows the annual net assets of Yifeng Pharmacy from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥11.39 Billion | +9.06% |
| 2023-12-31 | CN¥10.45 Billion | +14.53% |
| 2022-12-31 | CN¥9.12 Billion | +15.98% |
| 2021-12-31 | CN¥7.86 Billion | +36.02% |
| 2020-12-31 | CN¥5.78 Billion | +22.79% |
| 2019-12-31 | CN¥4.71 Billion | +12.93% |
| 2018-12-31 | CN¥4.17 Billion | +31.14% |
| 2017-12-31 | CN¥3.18 Billion | +6.87% |
| 2016-12-31 | CN¥2.98 Billion | +109.62% |
| 2015-12-31 | CN¥1.42 Billion | +138.25% |
| 2014-12-31 | CN¥595.76 Million | +18.63% |
| 2013-12-31 | CN¥502.20 Million | +17.94% |
| 2012-12-31 | CN¥425.82 Million | +19.52% |
| 2011-12-31 | CN¥356.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Yifeng Pharmacy's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15261.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥5.37 Billion | 50.04% |
| Common Stock | CN¥1.21 Billion | 11.30% |
| Other Components | CN¥4.15 Billion | 38.66% |
| Total Equity | CN¥10.73 Billion | 100.00% |
Yifeng Pharmacy Competitors by Market Cap
The table below lists competitors of Yifeng Pharmacy ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bandhan Bank Limited
NSE:BANDHANBNK
|
$1.95 Billion |
|
Park Hotels & Resorts Inc
NYSE:PK
|
$1.95 Billion |
|
Meta Financial Group Inc
NASDAQ:CASH
|
$1.95 Billion |
|
Advanced Technology & Materials Co Ltd
SHE:000969
|
$1.95 Billion |
|
Danieli & C RSP
LSE:0N4I
|
$1.94 Billion |
|
Hyundai Autoever Corp
KO:307950
|
$1.94 Billion |
|
ITC HOTELS LIMITED
NSE:ITCHOTELS
|
$1.94 Billion |
|
RBL Bank Limited
NSE:RBLBANK
|
$1.94 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yifeng Pharmacy's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,804,432,476 to 10,725,687,023, a change of 921,254,547 (9.4%).
- Net income of 1,528,576,670 contributed positively to equity growth.
- Dividend payments of 846,543,834 reduced retained earnings.
- Share repurchases of 3,998,723 reduced equity.
- Other factors increased equity by 243,220,434.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.53 Billion | +14.25% |
| Dividends Paid | CN¥846.54 Million | -7.89% |
| Share Repurchases | CN¥4.00 Million | -0.04% |
| Other Changes | CN¥243.22 Million | +2.27% |
| Total Change | CN¥- | 9.40% |
Book Value vs Market Value Analysis
This analysis compares Yifeng Pharmacy's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 42.08x to 2.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.58 | CN¥24.59 | x |
| 2012-12-31 | CN¥0.69 | CN¥24.59 | x |
| 2013-12-31 | CN¥0.82 | CN¥24.59 | x |
| 2014-12-31 | CN¥0.97 | CN¥24.59 | x |
| 2015-12-31 | CN¥1.79 | CN¥24.59 | x |
| 2016-12-31 | CN¥3.44 | CN¥24.59 | x |
| 2017-12-31 | CN¥3.43 | CN¥24.59 | x |
| 2018-12-31 | CN¥4.38 | CN¥24.59 | x |
| 2019-12-31 | CN¥4.69 | CN¥24.59 | x |
| 2020-12-31 | CN¥5.65 | CN¥24.59 | x |
| 2021-12-31 | CN¥7.46 | CN¥24.59 | x |
| 2022-12-31 | CN¥8.50 | CN¥24.59 | x |
| 2023-12-31 | CN¥8.12 | CN¥24.59 | x |
| 2024-12-31 | CN¥8.70 | CN¥24.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yifeng Pharmacy utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.25%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.35%
- • Asset Turnover: 0.86x
- • Equity Multiplier: 2.61x
- Recent ROE (14.25%) is above the historical average (14.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 15.78% | 4.56% | 1.45x | 2.38x | CN¥20.48 Million |
| 2012 | 16.23% | 4.46% | 1.82x | 2.00x | CN¥26.34 Million |
| 2013 | 19.92% | 5.50% | 1.76x | 2.06x | CN¥49.41 Million |
| 2014 | 23.81% | 6.30% | 1.78x | 2.12x | CN¥81.52 Million |
| 2015 | 12.46% | 6.18% | 1.17x | 1.73x | CN¥34.77 Million |
| 2016 | 7.56% | 6.00% | 0.88x | 1.42x | CN¥-72.36 Million |
| 2017 | 9.90% | 6.52% | 1.01x | 1.51x | CN¥-3.22 Million |
| 2018 | 10.26% | 6.02% | 0.88x | 1.94x | CN¥10.54 Million |
| 2019 | 12.06% | 5.29% | 1.12x | 2.04x | CN¥92.92 Million |
| 2020 | 13.60% | 5.66% | 1.02x | 2.37x | CN¥196.66 Million |
| 2021 | 11.87% | 5.79% | 0.90x | 2.28x | CN¥139.75 Million |
| 2022 | 14.75% | 6.35% | 0.95x | 2.46x | CN¥406.23 Million |
| 2023 | 14.40% | 6.25% | 0.94x | 2.46x | CN¥431.54 Million |
| 2024 | 14.25% | 6.35% | 0.86x | 2.61x | CN¥456.01 Million |
Industry Comparison
This section compares Yifeng Pharmacy's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $2,051,499,572
- Average return on equity (ROE) among peers: 9.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yifeng Pharmacy (603939) | CN¥11.66 Billion | 15.78% | 1.24x | $1.94 Billion |
| Cachet Pharmaceutical Co Ltd (002462) | $4.92 Billion | 13.40% | 1.65x | $437.62 Million |
| Yunnan Hongxiang Yixintang (002727) | $497.43 Million | 20.70% | 1.22x | $545.21 Million |
| Luyan Pharma Co Ltd (002788) | $746.00 Million | 15.21% | 3.60x | $450.11 Million |
| Ji Yao Holding Group Co Ltd (300108) | $-366.31 Million | 0.00% | 0.00x | $18.23 Million |
| Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) | $856.04 Million | 6.95% | 0.97x | $170.91 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $2.27 Billion | 10.12% | 2.47x | $188.58 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $1.78 Billion | 1.93% | 1.96x | $174.48 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $1.98 Billion | 5.80% | 1.33x | $323.73 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $736.00 Million | 6.25% | 0.61x | $180.65 Million |
| Laobaixing Pharmacy (603883) | $7.10 Billion | 11.06% | 2.01x | $739.96 Million |